Grants for Public and State controlled institutions of higher education - Health

This grant provides funding for research projects that improve mental health services and outcomes for young people experiencing early stages of psychosis by promoting data-driven care and collaboration among specialized treatment programs across the United States.

This funding opportunity provides financial support for organizations to archive and document child health and human development data sets, facilitating their accessibility for secondary analysis by researchers.

This funding opportunity provides financial support for researchers and organizations developing innovative long-acting treatments for HIV and related co-infections, aiming to improve patient adherence and health outcomes.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development and validation of reagents/tools to support research to characterize cellular and molecular constituents of the bat immune system and for the study of protective innate and adaptive immune mechanisms in bats. The Research Resource Program established by this NOFO will participate within a collaborative research network to advance understanding of the bat immune response. This NOFO will support the establishment and operation of a Bat Immunology Research Resource Program for the development and validation of reagents/tools for use in immunological studies using the bat model system. The recipient will participate in the Bat Immunology Network, which will consist of the Research Resource Program, the research projects supported by RFA-AI-23-068, and possible other participants as determined by NIAID. The Research Resource Program will conduct reagent/tool development and validation using appropriate systems, which includes testing against multiple bat species. While other members of the Bat Immunology Network may assist in validation efforts, reagent/tool validation is the responsibility of the Research Resource Program. Reagents/tools developed by the Research Resource Program will be provided to the research projects of the Bat Immunology Network. Reagents/tools will be made available to the broader research community through technology transfer arrangements, deposition to nonprofit repositories, and/or timely transfer to industry for commercialization. Areas of high priority include, but are not limited to, the development and validation of the following: Soluble immune molecules (e.g., cytokines, chemokines) for use in tissue culture or in vivo animal studies Antibodies or other probes/detection markers for use in cellular phenotyping, functional studies and/or immunoassays

This grant provides funding to K-12 schools, healthcare facilities, and faith-based organizations in Arizona to create and maintain sustainable green spaces that improve environmental quality and community well-being.

This funding opportunity supports innovative research aimed at developing new strategies for curing HIV at the start of antiretroviral therapy, targeting researchers and institutions focused on reducing the HIV reservoir and improving immune responses.

This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities.The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Transition to the R33 phase is not guaranteed for all grants awarded under this FOA. Continuation from the R21 phase to the R33 phase will be determined by AHRQ staff based on progress achieved in the R21 phase and factors such as program priorities and availability of funds.

The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.The purpose of this Funding Opportunity Announcement (FOA) is to support epidemiologic studies that utilize creative and innovative approaches to studying vision diseases and disorders with high public impact and whose findings will inform prevention and treatment strategies as well as basic sciences research. Background: Clinical vision research projects, including epidemiologic studies, are part of NEI’s core strategy for improving visual health and decreasing visual impairment in populations through research on the burden of disease, its causes, diagnosis, prevention, treatment and rehabilitation. Projects should focus on NEI’s mission to protect and improve visual health including, but not limited to: Determining the burden of eye diseases and their visual outcomes in a changing population, particularly disparities in the burden and the influences of sociocultural, environmental, economic, and demographic factors. Improving early diagnosis of ocular diseases and their underlying processes through new screening and detection strategies. Determining risk factors for ocular diseases. Identifying and assessing strategies that will overcome barriers to eye care and convert evidence-based findings into improved patient and population outcomes. Studying the interplay of factors that exacerbate or mitigate risk for eye diseases. The NEI encourages applications to support ocular epidemiologic research. These projects are supported under the cooperative agreement mechanism. Applicants are strongly encouraged to contact Scientific/Research staff as plans for an application are being developed (see Section VII, Agency Contacts), preferably no later than 12 weeks prior to the anticipated application submission date.

Despite huge advances in the development of novel medical therapies, Americans still live with poor health outcomes and suffer from the ill-effects of disease. Current medical research and the medical delivery system in the United States focus primarily on the reactive treatment of illnesses, despite the fact that many diseases or their ill-effects are preventable.The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that 1) population-level improvements in access to and uptake of disease prevention and wellness-promoting behaviors and 2) development of novel early-detection methods and prophylactic interventions could drastically improve the health of American throughout their lives, and 3) that system level innovations are required for delivery of proactive health effectively. Specific PHO interest areas include:Novel prevention, detection and prophylactic treatment methods for disease: Novel and scalable methods for early detection of disease and illness including the use of low/no-cost sensing modalities. Prophylactic approaches to prevention of diseases and harmful disease outcomes. Methods for continuous and widespread sensing of health state and early disease indicators that can be deployed at population-scale.Population-level approaches to increase the adoption of prevention and wellness behaviors: Early indicators of disease and pre-disease states and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness building methods for individuals. Methods to inform and educate individuals about healthy behaviors including lifestyle and preventative medical measures. Methods that incentivize individuals to adopt and maintain healthy behaviors. Novel approaches to increasing individual healthspan and independence even in the absence of disease.System innovation for the delivery of proactive health outcomes: Novel, robust and predictive surrogates for long-term health outcomes with associated epidemiological models. Valuation models for long-term treatment effects for vaccination, screening and other public health interventions. New funding and delivery models for preventative intervention.Other high-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy advocacy, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on the development of innovative technologies for analyzing molecular or cellular aspects of cancer, with the goal of improving cancer biology research, early detection, diagnosis, treatment, control, epidemiology, and addressing health disparities related to cancer.

The National Institutes of Health (NIH) has announced a funding opportunity titled Co-infection and Cancer (R01 Clinical Trial Not Allowed) under Funding Opportunity Number PAR-25-082. This initiative, led by the National Cancer Institute (NCI), is aimed at advancing research into the roles of co-infection in cancer development and progression. Co-infection is defined as the occurrence of two or more infections, whether simultaneous or sequential, involving pathogens or non-pathogenic agents, including viruses, bacteria, and parasites. The goal of this program is to explore how these co-infections contribute to cancer risk and progression and identify potential strategies for cancer prevention and treatment. The program encourages investigations that focus on co-infections with known oncogenic agents, excluding human immunodeficiency virus (HIV), and seeks studies that can lead to new opportunities in cancer treatment and prevention. In addition to pathogenic agents, research that includes the role of non-pathogenic agents, such as those in the microbiome, will be considered responsive. The program supports projects that delve into uncharted areas of co-infection and cancer, with an emphasis on mechanistic and epidemiologic research that could have practical implications for cancer control. Applicants are encouraged to focus on differences in cancer susceptibility, progression, and survival among diverse populations, including those that are racially or ethnically diverse, as well as medically underserved communities. International collaborations are also supported, particularly for studies in low- and middle-income countries where infection-associated cancers are more prevalent. The first submission date is January 5, 2025, with application due dates beginning on February 5, 2025. Budgets are not limited but must align with the scope of the project, and the maximum project period is five years. Applications must be submitted electronically through NIH's ASSIST system or Grants.gov. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign entities. The program seeks to support well-developed research projects backed by preliminary data. Studies that focus solely on co-infection with HIV or involve only a single pathogen will not be considered responsive. Evaluation criteria include the scientific merit of the project, innovation, and feasibility, as well as the expertise of the research team. This funding opportunity offers a unique chance to explore how co-infections contribute to cancer and potentially uncover new strategies for prevention and treatment across diverse populations.

This funding opportunity supports research that provides critical data to help the FDA regulate tobacco products, targeting a wide range of organizations, including nonprofits, educational institutions, and community groups, to improve public health outcomes related to tobacco use.

This funding opportunity supports innovative researchers in the U.S. who are tackling significant challenges in diabetes, metabolic diseases, digestive disorders, and nutrition, with the goal of advancing groundbreaking scientific understanding and treatment.

The Southern Sustainable Agriculture Research & Education (SSARE) Education Grants program is designed to fund education and outreach activities that benefit the sustainable agriculture community. This grant directly aligns with SSARE's mission to promote efforts in farmer innovations, community resilience, business success, agricultural diversification, and best management practices. The core objective is to support projects that develop sustainable agriculture systems or move existing systems towards sustainability. The primary beneficiaries of these grants are farmers and farming communities, including those involved in indigenous agriculture producing for community food systems. Academic institutions, non-profits, non-governmental organizations (NGOs), 1890 land-grant university faculty/extension cooperators, 1862 land-grant universities, other colleges and universities, and government agencies are eligible to apply, acting as facilitators for these educational initiatives. The impact goals are centered on fostering a more sustainable, resilient, and economically viable agricultural sector through knowledge dissemination and practical application. Education Grants prioritize projects that clearly articulate what is being taught, to whom, and how the goals will be accomplished. Focus areas include experiential learning (demonstrations, on-farm tours, field days, workshops), integrative approaches (conferences, seminars, course curriculum), and reinforcement methods (fact sheets, bulletins, videos, online technologies). SSARE also encourages proposals on quality of life topics, such as heirs property, farmers’ markets, food hubs, local/regional processing, and urban agriculture systems, emphasizing the social health of farming systems. Expected outcomes include the adoption of sustainable agriculture practices, enhanced farmer innovation, increased community resilience, improved business success for agricultural enterprises, and greater agricultural diversification. Projects should yield results that are realistic, acceptable to farmers, logical, and capable of leading to tangible actions and benefits described in the proposal. The grant projects are strictly focused on education and outreach, with no research component, and are paid by reimbursement of allowable expenses. The foundation's strategic priorities are evident in the grant requirements, which mandate that project outcomes focus on sustainable agriculture systems and clearly demonstrate how education and outreach efforts will be implemented and evaluated. The theory of change underpinning this program is that by providing targeted education and outreach, knowledge and best practices will be transferred to farmers and communities, leading to the development and widespread adoption of sustainable agricultural methods and improved quality of life within farming systems. Project maximums are $50,000, with a duration limited to two years. Applicants from the Southern region, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, Puerto Rico, and the U.S. Virgin Islands, are eligible. Farmers involved in these projects must have farming/ranching as their primary occupation or part-time farming with at least $1,000 of documented annual income from their operation, with exceptions for indigenous agriculture.

The Kenneth A. Scott Charitable Trust's grant program aims to enhance the quality of life for companion animals and native wildlife. This mission aligns with the foundation's core belief in supporting innovative projects that go beyond basic care, providing long-term benefits for animals today and in the future. The trust focuses on helping organizations deliver an enhanced quality of life for homeless and abused companion animals. The target beneficiaries of this grant program include homeless and abused companion animals, native wildlife, and owned companion animals in under-resourced urban/rural areas or those owned by socially vulnerable populations. Impact goals include increasing successful adoptions, improving staff and volunteer care delivery, promoting humane education, enhancing access to medical care, and controlling pet and feral animal populations through spay/neuter initiatives. The program prioritizes several key areas: animal adoption, behavior training, and fostering; continuing education and training for staff and volunteers; humane and wildlife education; medical care, rehabilitation, and wellness care for animals; pet and feral animal population control through spay/neuter; equipment directly benefiting animals; and other animal care initiatives that celebrate the human-animal bond. Preferred projects include non-capital means of expanding shelter capacity, opportunities for staff and volunteer development, school and community programs addressing humane care, and assistance for owned pets from under-resourced households. Expected outcomes and measurable results include increased successful adoptions, improved delivery of care by staff and volunteers, enhanced community understanding of animal welfare, better access to medical care for vulnerable animal populations, and a reduction in unwanted pet populations. The foundation's strategic priorities are centered on supporting initiatives that lead to a high quality of life for individual animals and significant improvements for large numbers of animals. Their theory of change is that by funding innovative projects and supporting eligible organizations, they can foster better humane care, improve animal well-being, and address critical issues such as overpopulation and lack of access to care, ultimately creating a more compassionate environment for animals.

This funding opportunity supports postdoctoral researchers from underrepresented groups in cancer research as they transition to independent faculty positions, providing salary and research funding to help establish their own research programs.

This funding opportunity supports innovative clinical research to explore the brain mechanisms behind substance use disorders, targeting a wide range of researchers and institutions dedicated to addressing addiction challenges.

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

This funding opportunity provides financial support for researchers to analyze and integrate existing data to better understand cancer risk, prevention, and treatment outcomes, particularly focusing on innovative methodologies and addressing health disparities.

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. HSF expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. HSF supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change.Considering the current healthcare challenges that we face today, the goal of achieving better health outcomes is a moving target that requires daring and adaptable solutions. HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support:Breakthrough Technologies: Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions. Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods. Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need. Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems. Novel approaches to diagnose and treat diseases of the lymphatic system, particularly rare diseases, with a focus on the effects of genetic expression in the lymphatic system and/or models demonstrating the relationship between lymphatic dysfunction and health and disease.Transformative Tools: Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care. Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease. Development of bionics to restore sight, hearing, taste, or smell. Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders. Synthetic biology approaches to diagnosing, treating, and/or curing a multitude of diseases. Novel physics and/or chemistry-based approaches to improve imaging that reduces cost, increases availability, expands capability, improves resolution, reduces exposure to radiation, and accommodates pediatric patient populations. Integrated sensing and delivery devices for treating and diagnosing chronic health conditions, including mental health conditions or substance use disorders. Miniaturization of complex hardware to enable broader access to pediatric and other patient populations, as well as portability, such as diagnostic, treatment, imaging, or other devices.Platform Systems: Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs Novel molecular platform approaches, including the modulation of host systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes. New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed. Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.